A detailed history of Lynch & Associates transactions in Eli Lilly & CO stock. As of the latest transaction made, Lynch & Associates holds 7,621 shares of LLY stock, worth $6.14 Million. This represents 1.44% of its overall portfolio holdings.

Number of Shares
7,621
Previous 7,721 1.3%
Holding current value
$6.14 Million
Previous $6.99 Million 3.42%
% of portfolio
1.44%
Previous 1.59%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$772.14 - $960.02 $77,214 - $96,002
-100 Reduced 1.3%
7,621 $6.75 Million
Q1 2024

Apr 09, 2024

BUY
$592.2 - $792.28 $84,684 - $113,296
143 Added 1.89%
7,721 $6.01 Million
Q4 2023

Jan 08, 2024

SELL
$525.19 - $619.13 $55,670 - $65,627
-106 Reduced 1.38%
7,578 $4.42 Million
Q3 2023

Oct 24, 2023

SELL
$434.7 - $599.3 $10,867 - $14,982
-25 Reduced 0.32%
7,684 $4.13 Million
Q2 2023

Oct 24, 2023

SELL
$350.74 - $468.98 $122,057 - $163,205
-348 Reduced 4.32%
7,709 $3.62 Million
Q2 2023

Jul 13, 2023

SELL
$350.74 - $468.98 $122,057 - $163,205
-348 Reduced 4.32%
7,709 $3.62 Million
Q1 2023

Oct 24, 2023

BUY
$310.63 - $364.82 $108,099 - $126,957
348 Added 4.51%
8,057 $2.77 Million
Q1 2023

Apr 04, 2023

BUY
$310.63 - $364.82 $71,444 - $83,908
230 Added 2.94%
8,057 $2.77 Million
Q4 2022

Oct 24, 2023

BUY
$321.55 - $374.67 $45,981 - $53,577
143 Added 1.86%
7,827 $2.86 Million
Q3 2022

Oct 03, 2022

SELL
$296.48 - $337.87 $1,482 - $1,689
-5 Reduced 0.06%
7,827 $2.53 Million
Q2 2022

Jul 06, 2022

SELL
$278.73 - $327.27 $27,873 - $32,727
-100 Reduced 1.26%
7,832 $2.54 Million
Q1 2022

Apr 08, 2022

SELL
$234.69 - $291.66 $5,867 - $7,291
-25 Reduced 0.31%
7,932 $2.27 Million
Q4 2021

Jan 11, 2022

SELL
$224.85 - $279.04 $112,425 - $139,520
-500 Reduced 5.91%
7,957 $2.2 Million
Q1 2021

Apr 09, 2021

SELL
$164.32 - $212.72 $4,108 - $5,318
-25 Reduced 0.29%
8,457 $1.58 Million
Q4 2020

Jan 20, 2021

BUY
$130.46 - $172.63 $130,460 - $172,630
1,000 Added 13.37%
8,482 $1.43 Million
Q3 2020

Oct 21, 2020

BUY
$146.22 - $169.13 $288,784 - $334,031
1,975 Added 35.86%
7,482 $1.11 Million
Q1 2020

Apr 28, 2020

SELL
$119.05 - $147.35 $18,690 - $23,133
-157 Reduced 2.77%
5,507 $764,000
Q3 2019

Oct 03, 2019

SELL
$106.79 - $116.16 $40,046 - $43,560
-375 Reduced 6.21%
5,664 $633,000
Q4 2018

Jan 10, 2019

SELL
$105.9 - $118.64 $15,885 - $17,796
-150 Reduced 2.42%
6,039 $699,000
Q3 2018

Oct 05, 2018

SELL
$85.86 - $107.31 $8,586 - $10,731
-100 Reduced 1.59%
6,189 $664,000
Q2 2018

Jul 09, 2018

SELL
$75.7 - $86.88 $908 - $1,042
-12 Reduced 0.19%
6,289 $537,000
Q1 2018

Apr 06, 2018

BUY
$74.21 - $87.6 $7,420 - $8,760
100 Added 1.61%
6,301 $488,000
Q4 2017

Jan 04, 2018

SELL
$81.94 - $87.89 $8,194 - $8,789
-100 Reduced 1.59%
6,201 $524,000
Q3 2017

Oct 18, 2017

BUY
$77.07 - $85.54 $485,618 - $538,987
6,301
6,301 $539,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $766B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Lynch & Associates Portfolio

Follow Lynch & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynch & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Lynch & Associates with notifications on news.